来自官方财务报表的收入、利润与现金流历史。
Edwards Lifesciences Corporation 在美国、欧洲、日本和国际上提供治疗晚期心血管疾病的产品和技术。它提供经导管心脏瓣膜置换产品，用于 Edwards SAPIEN 系列瓣膜系统下的主动脉心脏瓣膜微创置换； PASCAL 和 EVOQUE 品牌的经导管心脏瓣膜修复和置换产品，用于治疗二尖瓣和三尖瓣疾病。该公司还提供外科结构心脏解决方案，例如 INSPIRIS 品牌的主动脉手术瓣膜； INSPIRIS RESILIA 主动脉瓣，提供 RESILIA 组织和 VFit 技术； KONECT RESILIA，一种用于复杂组合手术的预组装组织瓣膜导管；和 MITRIS RESILIA 阀门。它通过直销队伍和独立分销商分销其产品。 Edwards Lifesciences Corporation 成立于 1958 年，总部位于加利福尼亚州欧文市。
机器翻译
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $6.5B | $6.1B | $5.4B | $6.0B | $5.4B | $5.2B | $4.4B | $4.3B | $3.7B | $3.4B | $3.0B | $2.5B | $2.3B | $2.0B | $1.9B | $1.7B | $1.4B | $1.3B | $1.2B | $1.1B | $1.0B |
| 毛利 | $5.1B | $4.7B | $4.3B | $4.6B | $4.2B | $4.0B | $3.3B | $3.2B | $2.8B | $2.6B | $2.2B | $1.8B | $1.7B | $1.5B | $1.4B | $1.2B | $1.0B | $922M | $829M | $710M | $654M |
| 毛利率% | 78.0% | 78.1% | 79.5% | 77.0% | 78.3% | 76.6% | 74.9% | 73.4% | 75.2% | 74.3% | 72.8% | 72.6% | 72.8% | 73.4% | 73.3% | 72.5% | 71.7% | 69.8% | 67.0% | 65.0% | 63.0% |
| 营业利润（EBIT） | $1.8B | $1.6B | $1.4B | $1.5B | $1.7B | $1.6B | $1.3B | $1.2B | $1.1B | $1.0B | $816M | $576M | $487M | $433M | $397M | $329M | $282M | $238M | $209M | $170M | $164M |
| 营业利润率% | 28.1% | 27.0% | 25.4% | 25.6% | 31.6% | 30.8% | 29.5% | 27.6% | 29.3% | 29.4% | 27.5% | 23.1% | 21.0% | 21.2% | 20.9% | 19.6% | 19.5% | 18.0% | 16.9% | 15.5% | 15.8% |
| 净利 | $1.0B | $1.1B | $4.2B | $1.4B | $1.5B | $1.5B | $823M | $1.0B | $722M | $622M | $570M | $495M | $811M | $392M | $293M | $237M | $218M | $229M | $129M | $113M | $130M |
| 净利润率 % | 15.4% | 17.7% | 76.8% | 23.4% | 28.3% | 28.7% | 18.8% | 24.1% | 19.4% | 18.1% | 19.2% | 19.9% | 34.9% | 19.1% | 15.4% | 14.1% | 15.1% | 17.3% | 10.4% | 10.4% | 12.6% |
| EBITDA | $1.5B | $1.4B | $1.7B | $1.5B | $2.0B | $1.9B | $1.1B | $1.3B | $872M | $1.1B | $827M | $707M | $1.2B | $590M | $453M | $345M | $327M | $297M | $227M | $214M | $240M |
| 每股收益（EPS） | $1.73 | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 | $1.30 | $1.64 | $1.13 | $0.96 | $0.87 | $0.75 | $1.25 | $0.57 | $0.41 | $0.33 | $0.30 | $0.33 | $0.18 | $0.15 | $0.17 |
| 已发行股数 (M) | 578M | 586M | 599M | 609M | 624M | 631M | 632M | 637M | 641M | 648M | 653M | 661M | 651M | 683M | 710M | 716M | 715M | 704M | 715M | 752M | 767M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 EW 交互式查看器。 /companies/us/EW
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms